What is it about?
This study investigates three clinical isolates of Aspergillus hortae, a rare fungal species associated with human infections. We performed whole-genome sequencing, analyzed their growth characteristics under different laboratory conditions, and evaluated their susceptibility to commonly used antifungal drugs. By combining genomic data with phenotypic and antifungal susceptibility testing, we aimed to better understand the biological features and clinical behavior of this uncommon pathogen.
Featured Image
Photo by Shubham Dhage on Unsplash
Why is it important?
Rare fungal species are increasingly being detected in clinical settings, but many remain poorly characterized. Limited genomic and antifungal susceptibility data can delay accurate diagnosis and appropriate treatment. By providing detailed genomic information and antifungal response profiles for A. hortae, this study improves species identification, supports informed therapeutic decisions, and contributes to global knowledge of emerging fungal pathogens. This is particularly relevant in regions where genomic surveillance of fungi is still developing.
Perspectives
Our findings highlight the value of integrating genomics with traditional microbiological approaches to better understand emerging fungal pathogens. Future research should expand genomic surveillance of rare Aspergillus species and explore potential resistance mechanisms. Strengthening fungal genomics capacity in Latin America and other underrepresented regions will be essential to improve diagnosis, treatment, and public health responses to invasive fungal infections.
Oscar Gomez
Universidad de Antioquia
Read the Original
This page is a summary of: Whole-genome sequencing, phenotypic characterization, and antifungal susceptibility profiles of three Aspergillus hortae clinical isolates from Colombia, PLOS One, February 2026, PLOS,
DOI: 10.1371/journal.pone.0342479.
You can read the full text:
Contributors
The following have contributed to this page
